Efficacy, Comparative Effectiveness, and Harm of Respiratory Syncytial Virus Vaccines in Adults Who Are Not Pregnant or Immunocompromised: A Rapid Review for the American College of Physicians - PubMe

5 hours ago

RSV causes significant respiratory disease in older adults and those with comorbidities.
The review analyzed RSV vaccine efficacy, effectiveness, and harm in nonpregnant, non-immunocompromised adults.
Data sources included Ovid Medline, Embase, ClinicalTrials.gov, and a Cochrane review.
Seven randomized controlled trials and one nonrandomized study were included.
Protein subunit vaccines likely reduce RSV-related hospitalizations and severe illness in adults ≥60 years.
No significant effect on all-cause mortality or serious adverse events was found for protein subunit vaccines.
mRNA vaccines showed no difference in serious adverse events compared to placebo in older adults.
Evidence on RSV vaccines in younger adults and mRNA vaccine efficacy remains insufficient.
Primary funding was provided by the American College of Physicians.

Hasty Briefsbeta